[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-363702-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-363702-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","nanomedicine-meets-immunotherapy-advancing-adoptive-cell-therapy-with-nanoparticles-in-the-treatment-of-cancer-with-sustainability-perspectives","Nanomedicine Meets Immunotherapy - Advancing Adoptive Cell Therapy with Nanoparticles in the Treatment of Cancer with Sustainability Perspectives","","Immunotherapy has achieved notable clinical success in some cancers, especially via adoptive cell therapy (ACT) using T cells engineered with chimeric antigen receptors (CAR). Yet solid tumors limit efficacy because of scarce tumor-specific antigens, antigen heterogeneity, an immunosuppressive tumor microenvironment, and physical barriers that obstruct T cell infiltration by dense extracellular matrix. Nanoparticle (NP) strategies can address these obstacles by enhancing tumor immunogenicity and vascular permeability while lowering off-target toxicity.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/nanomedicine-meets-immunotherapy-advancing-adoptive-cell-therapy-with-nanoparticles-in-the-treatment-of-cancer-with-sustainability-perspectives/363702/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/nanomedicine-meets-immunotherapy-advancing-adoptive-cell-therapy-with-nanoparticles-in-the-treatment-of-cancer-with-sustainability-perspectives/363702.png","ImageObject",300,407,{"name":42,"@type":43},"Mary Man","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What are the main limitations of adoptive cell therapy (ACT) in solid tumors?","Question",{"text":63,"@type":64},"ACT efficacy in solid tumors is limited by insufficient tumor-specific antigens, antigen heterogeneity, immunosuppressive tumor microenvironments, and dense extracellular matrix that physically blocks T cell infiltration.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How can nanoparticle-based approaches improve ACT outcomes?",{"text":68,"@type":64},"Nanoparticles can enhance ACT by improving tumor immunogenicity and vascular permeability, and by reducing off-target toxicity to healthy tissues.",{"name":70,"@type":61,"acceptedAnswer":71},"Which nanoparticle-enabled strategies are discussed for advancing ACT?",{"text":72,"@type":64},"The review covers strategies such as delivering immunomodulators and chemotherapeutics, NP-mediated hyperthermia, magnetic guidance to increase T cell accumulation in tumors, and in vivo NP-mediated generation and activation of CAR T cells.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},363702,1790507550,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},7421720224475,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Advanced Science  \nSPECIAL ISSUE Advances in Cancer Immunotherapy  \n[www.advancedscience.com](www.advancedscience.com)  \n REVIEW   \nNanomedicine Meets Immunotherapy: Advancing Adoptive Cell Therapy with Nanoparticles in the Treatment of Cancer with Sustainability Perspectives  \nErica Frostegård1  Tatiana Bobrova2  Amalie Leinebø3  Thibault Leray4, 5  Shayamita Ghosh6   \nLorena García-Hevia6  Chiara Puccinelli7  Lorenzo Riccio7  Jacopo Sorani8  Davide Bonifazi7  Julien Caumartin9 Emmanuel Donnadieu2  Florence Gazeau3  Roland Hischier8  Else Marit Inderberg4  Mónica L. Fanarraga6  Maria Loustau9  Bernd Nowack8  Sébastien Wälchli4  Cécilia Ménard-Moyon1, 10   \n1 CNRS, Immunology, Immunopathology and Therapeutic Chemistry, UPR 3572, University of Strasbourg, Strasbourg, France  2 INSERM UMR 1186, Integrative Tumor Immunology and Immunotherapy, Gustave Roussy, Fac. de Médecine-University Paris-Sud, Université Paris-Saclay, Villejuif, France  3University of Paris City, CNRS, Inserm, NABI, Paris, France  4Translational Research Unit, Section for Cellular Therapy, Department of Oncology, Oslo University Hospital, Oslo, Norway  5Medical Faculty, University of Oslo, Oslo, Norway  6The Nanomedicine Group, Universidad de Cantabria-Instituto de Investigación Valdecilla-IDIVAL Avda Herrera Oria s/n, Santander, Spain  7 Institute of Organic Chemistry, Faculty of Chemistry, University of Vienna, Vienna, Austria   \n8 Swiss Federal Laboratories for Materials Science and Technology (Empa), Technology and Society Laboratory, St. Gallen, Switzerland  9 Exosiris, Le Vésinet,  \nFrance  10University of Strasbourg Institute of Advanced Study (USIAS), Strasbourg, France Correspondence: Cécilia Ménard-Moyon ([c.menard@ibmc-cnrs.unistra.fr](c.menard@ibmc-cnrs.unistra.fr))  \nReceived: 11 November 2025  Revised: 2 February 2026  Accepted: 2 February 2026  \nKeywords: chimeric antigen receptor | drug delivery | immunomodulator | magnetic hyperthermia | photothermal therapy  \nABSTRACT  \nImmunotherapy has achieved remarkable clinical success in certain cancers, particularly through adoptive cell therapy (ACT), where T cell engineering with chimeric antigen receptor (CAR) has driven major clinical breakthroughs in the treatment of hematologic malignancies. However, efficacy against solid tumors remains limited due to multiple barriers, including the scarcity of tumor-specific antigens, antigen heterogeneity, immunosuppressive tumor microenvironment, and physical obstruction of T cell infiltration by dense extracellular matrix. Nanoparticle (NP)-based approaches can overcome these obstacles and enhance ACT by improving tumor immunogenicity and vascular permeability, while reducing off-target toxicity to healthy tissues. This review discusses different strategies leveraging NPs to enhance ACT, including the delivery of immunomodulators and chemotherapeutics, NP-mediated hyperthermia, magnetic guidance to improve T cell accumulation in tumors, and in vivo NPmediated generation and activation of CAR T cells. While prioritizing patient safety is essential, it does not fully reflect the range of risks and challenges associated with novel nanomedicines. In this regard, we discuss how integrating environmental impact assessments early in the development process is crucial for identifying key impact areas of concern and steering innovation towards more sustainable and responsible designs. Finally, we also identify current challenges, and discuss potential solutions and future research directions, including safety and sustainability.  \n\n| E. Frostegård, T. Bobrova, A. Leinebø, T. Leray, S. Ghosh, L. García-Hevia, C. Puccinelli, L. Riccio, and J. Sorani contributed equally to this review.\u003Cbr>|\n| --- |\n| This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.\u003Cbr>© 2026 The Author(s). Advanced Science published by Wiley-VCH GmbH |","cbCaibiiGvGoMvGc","https://ap.wps.com/l/cbCaibiiGvGoMvGc","pdf",6361569,39,"English","# Introduction\n## Adoptive Cell Therapy for Cancer Treatment","[{\"question\":\"What are the main limitations of adoptive cell therapy (ACT) in solid tumors?\",\"answer\":\"ACT efficacy in solid tumors is limited by insufficient tumor-specific antigens, antigen heterogeneity, immunosuppressive tumor microenvironments, and dense extracellular matrix that physically blocks T cell infiltration.\"},{\"question\":\"How can nanoparticle-based approaches improve ACT outcomes?\",\"answer\":\"Nanoparticles can enhance ACT by improving tumor immunogenicity and vascular permeability, and by reducing off-target toxicity to healthy tissues.\"},{\"question\":\"Which nanoparticle-enabled strategies are discussed for advancing ACT?\",\"answer\":\"The review covers strategies such as delivering immunomodulators and chemotherapeutics, NP-mediated hyperthermia, magnetic guidance to increase T cell accumulation in tumors, and in vivo NP-mediated generation and activation of CAR T cells.\"}]","Nanomedicine Meets Immunotherapy - Advancing Adoptive Cell Therapy with Nanoparticles in the Treatment of Cancer with Sustainability Perspectives | PDF",1790152731,98,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/17969328326498bc641671c7a8e5a02f.webp",983,1283,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/417c9e7a2dce19c1230e25e2ffb2dc20.webp",982,1281,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f3f81befa5d6d6f3aba7dee7bb5c227e.webp",981,1280,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8b3c7d4c64ee9072380afbd8a5e16fe4.webp",980,1279]